AzTrials
AzTrials

Sleep Apnea, ObstructivePhase 2OSANCT00273754

The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).

A Phase 2 study testing Caffeine in people with Sleep Apnea, Obstructive and Tonsillectomy, run by The University of Texas Health Science Center, Houston at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a research study using caffeine in children who have an obstructive sleep apnea (OSA). OSA means children who stop breathing during their sleep due to obstruction in their airway. Read more about this study

Who is it for?
Ages 30 months to 18 years
What is being tested?
Caffeine
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
74 participants
Where
1 siteUnited States
Study dates
Sep 2003to May 2008
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 months to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Children between 2.5-18 years old
  • Diagnosed with obstructive sleep apnea
  • Undergoing elective tonsillectomy and adenoidectomy

Who cannot join

  • Age below 2.5 or above 18 years

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Texas, Health Science Center at Houston, Children's Memorial Hermann Hospital

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: A Pilot Study to Evaluate if Caffeine Helps Children With Obstructive Sleep Apnea Recover Faster From Anesthesia, and With Less Complications After General Anesthesia for Tonsillectomy and Adenoidectomy.

This is a research study using caffeine in children who have an obstructive sleep apnea (OSA). OSA means children who stop breathing during their sleep due to obstruction in their airway. The purpose of this study is to determine whether caffeine when given in the vein, will wake children up faster and decrease post-anesthesia airway obstruction, as well as the safety and if the drug agrees with the child compared to a placebo (an inactive or dummy agent).

Read the detailed description

Patients with OSA are reported to have a higher rate of severe respiratory complications associated with upper airway obstruction during anesthesia and sedation or immediately after anesthesia. Children with OSA (especially those under three years of age, those with severe OSA, cerebral palsy or craniofacial anomalies) are at increased risks for post-operative complications, and require careful monitoring post-operatively.

Although the etiology of obstructive sleep apnea is mainly obstruction due to anatomical and neuromuscular abnormalities, we believe that a central element may contribute to OSA.

The aim of this study is to evaluate whether administration of caffeine to children with OSA, scheduled for elective T \& A under general anesthesia contributes to a faster recovery, less post-operative complications, and a shorter stay in the PACU, DSU and the hospital.

Being tested
Caffeine, Placebo
Keywords
Obstructive Sleep Apnea (OSA), Tonsillectomy and Adenoidectomy (T&A), Postoperative Complications, Recovery
Medical subject headings
Sleep Apnea, Obstructive, Postoperative Complications

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CaffeineDrug

    Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.

  • PlaceboDrug

    Also called Saline

    Children in group two will receive an amount of normal saline equal to Caffeine

Study groups in NCT00273754
Study groupRoleWhat they receive
PlaceboPlacebo comparatorSaline
Receives: Drug: Placebo
CaffeineActive comparatorCaffeine benzoate
Receives: Drug: Caffeine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo.

    The number of children having adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation <95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the Operating Room and in the PACU was recorded.

    Measured: Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room.

Secondary outcomes (5)
  1. Occurence of Post Extubatory Respiratory Adverse Events.

    The overall occurance of adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation <95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the OR and in the PACU was noted.

    Measured: Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room.

  2. Extubation Time.

    Time from end of anesthesia until extubation.

    Measured: Duration from anesthesia end until extubation time.

  3. Awakening Time

    A child with a Steward Recovery Scale score of 6 is defined as awake, coughing/crying, and has purposeful movements.

    Measured: Awakening time from end of anesthesia until the child reached a score of 6 on the Steward recovery score.

  4. Post Anesthesia Care Unit (PACU) Duration

    Measured: Time spent in PACU following surgical procedure prior to discharge home or hospital admission.

  5. Hospital Discharge Time

    Children were discharged from the hospital when they reached the hospital discharge criteria: they were awake, had stable vital signs, were breathing adequately, had O2 saturation >95% while breathing room air, were able to swallow fluids, had no or minimal pain, and were able to ambulate without excessive nausea, vomiting, or dizziness.

    Measured: Total time from end anesthesia to discharge home

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jan 2006 (estimated)
  2. Study startSep 2003
  3. Primary completionMay 2008
  4. Study completionMay 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
74 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00273754
Sponsor's protocol ID
HSC-MS-03-108
Acronym
OSA
Status last verified
May 2016
First submitted
4 Jan 2006
Last updated
16 Jun 2016
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Caffeine in people with Sleep Apnea, Obstructive and Tonsillectomy, run by The University of Texas Health Science Center, Houston at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 Nov 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. (time frame: Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in